Tag Archives: EACS

October, 2015

  • 23 October

    Gilead Announces Positive Results from its Late-Stage HIV Study

    BARCELONA, Spain–(BUSINESS WIRE)–Oct. 22, 2015– Gilead Sciences, Inc. (NASDAQ:GILD) today announced 96-week results from two Phase 3 studies (Studies 104 and 111) evaluating its investigational once-daily single tablet regimen (STR), Genvoya® (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg or E/C/F/TAF), for the treatment …